Clinical Trials Logo

Acute Kidney Injury (AKI) clinical trials

View clinical trials related to Acute Kidney Injury (AKI).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02620761 Terminated - Clinical trials for Acute Kidney Injury (AKI)

Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants

Fenaki
Start date: February 6, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators will conduct a prospective, blinded, randomized, placebo-controlled trial with a sample size of 20 patients in each of the two arms (fenoldopam vs placebo) based upon a difference in serum creatinine by one standard deviation. Fluid and salt intake will be held constant within clinical parameters and carefully measured. Fenoldopam will be started at 0.1 ug/kg/min. If, after 6 hrs there is no decrease in blood pressure, the dose will be increased to 0.2 ug/kg/min. This dose will be continued throughout the remainder of the study. A study of pediatric patients previously provided to the FDA showed no hypotension at a dose of 0.2 ug/kg/min. Fenoldopam will be started 12 hrs before the first dose of indomethacin and discontinued 12 hrs after the 3rd dose of indomethacin. Study samples will include both blood and urine. The primary outcome will be a reduction in renal dysfunction, as determined by creatinine and urine output over the course of treatment. Additional outcomes will include determination of known and novel metabolomic urine markers of renal dysfunction.